Welcome to our dedicated page for Geovax Labs news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs Inc (GOVXW) is a clinical-stage biotechnology company advancing vaccines and immunotherapies through its proprietary MVA-VLP platform. This news hub provides investors and industry professionals with timely updates on the company's developments in infectious disease and oncology research.
Access official press releases, clinical trial milestones, and strategic partnership announcements in one centralized location. Track progress across GeoVax's pipeline including COVID-19 boosters, cancer immunotherapies, and emerging infectious disease vaccines.
Key updates include regulatory filings, preclinical data disclosures, and manufacturing collaborations. Our curated news feed ensures you stay informed about critical developments affecting GeoVax's scientific progress and market position.
Bookmark this page for direct access to verified company communications and analysis-neutral reporting. Check regularly for essential updates on GeoVax's innovative approaches to preventive and therapeutic healthcare solutions.
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced key staff appointments to strengthen its operational resources for ongoing clinical trials for COVID-19 and advanced head & neck cancer. Jeffrey Welch has been appointed as Head, Process Development and Manufacturing Operations, while Erica Raiden takes on the role of Director, Clinical Operations. GeoVax also noted that Chief Scientific Officer Mark J. Newman, PhD, is now full-time. These changes aim to enhance manufacturing capacity and ensure timely advancement of clinical trials, including GEO-CM04S1 for COVID-19 and Gedeptin® for head and neck cancer.
GeoVax Labs, Inc. (Nasdaq: GOVX) will report its 2021 financial results on March 9, 2022, after market close. Following the release, management will host a conference call at 4:30 p.m. ET to review the results and provide updates on corporate developments. Interested participants can pre-register for the call or join via dial-in numbers. GeoVax is focused on developing vaccines and immunotherapies against infectious diseases and cancer, with ongoing clinical trials for COVID-19 and head and neck cancer treatments.
GeoVax Labs (Nasdaq: GOVX) announced that its Chairman & CEO, David Dodd, has been named a 2022 Georgia Titan 100, recognizing top business leaders in the state. This accolade highlights Dodd's exceptional leadership within the company, which is noted for developing vaccines and immunotherapies. The Titan 100 program celebrates influential executives whose companies collectively employ over 240,000 individuals and generate more than $66 billion in revenue. An awards ceremony will take place on May 12, 2022, at Zoo Atlanta.
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology firm focused on human vaccines and cancer therapies, announced that its Chairman and CEO, David Dodd, will present at the 2022 BIO CEO & Investor Digital Conference from February 14-17, 2022. Dodd will discuss the company’s product development, including updates on Phase 2 clinical trials for COVID-19 vaccines and head and neck cancer immunotherapy. GeoVax is also scheduling meetings with institutional investors. More information can be found on GeoVax’s website.
GeoVax Labs, Inc. (Nasdaq: GOVX) has successfully closed a private placement, issuing 707,484 shares of common stock and 2,360,000 pre-funded warrants to purchase common stock. The offering raised approximately $10 million before expenses, with shares sold at a price of $3.26 each. The funds will support clinical trial expenses, working capital, and corporate initiatives. The securities are not registered under the Securities Act of 1933 and were offered to accredited investors only. GeoVax is developing vaccines and therapies against infectious diseases and cancer.
GeoVax Labs, Inc. (Nasdaq: GOVX) has entered a securities purchase agreement with an institutional investor to raise approximately $10 million. This will be achieved through a private placement of 707,484 shares of common stock and 2,360,000 pre-funded warrants, allowing up to 3,067,484 shares to be purchased. Each share and accompanying warrant is sold at an effective price of $3.26. Closing is anticipated on January 19, 2022, pending customary conditions. The securities are not registered under the Securities Act and are offered exclusively to accredited investors.
GeoVax Labs, Inc. (GOVX) announced the engagement of CATO SMS to manage its Phase 1/2 clinical trial evaluating Gedeptin therapy for recurrent head and neck cancer. This therapy utilizes Gene-Directed Enzyme Prodrug Therapy (GDEPT) to target tumor cells. The trial, currently enrolling at Stanford University, aims to accelerate patient enrollment with plans to add two more sites. Funded by the FDA's Orphan Products Clinical Trials Grants Program, Gedeptin has also received orphan drug status for specific cancers. The company is optimistic about achieving clinical milestones with CATO SMS.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., as Chief Medical Officer, enhancing its leadership in vaccine development. Dr. McKee brings over 30 years of experience, particularly in vaccines and infectious diseases, having previously held key positions with the U.S. Army and various biopharmaceutical firms. His expertise is expected to strengthen GeoVax's clinical development and regulatory efforts, especially for ongoing vaccine trials against COVID-19 and other infectious diseases.
GeoVax Labs, Inc. (GOVX) announced that CEO David Dodd will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference from January 10-13, 2022. The focus will be on updates from three Phase 2 clinical trials for COVID-19 vaccines and immunotherapy for head and neck cancer. Dodd's presentation will be available on the conference website starting January 10 at 7:00 AM EST. Additionally, investor meetings are scheduled during the Biotech Showcase from January 17-19, 2022. GeoVax is developing novel vaccines and immunotherapies for infectious diseases and cancer.
GeoVax Labs CEO David Dodd's letter highlights significant 2021 achievements and outlines ambitious goals for 2022. Key accomplishments include advancing the COVID-19 vaccine GEO-CM04S1 into Phase 2 trials, which aim to enhance immune responses in both immunocompromised patients and healthy individuals as a booster. Development of the immuno-oncology therapy Gedeptin is also progressing, with FDA orphan drug status and planned expansions for patient enrollment. For 2022, GeoVax aims to accelerate its clinical trials in vaccines and immunotherapies while maintaining operational strength.
